NRT Petition Calls On FDA To Greatly Expand Indications, Availability
This article was originally published in The Tan Sheet
FDA's stated commitment to a public health approach to drug regulation will be put to the test by a petition to expand nicotine replacement therapy indications and availability
You may also be interested in...
Drug firms could educate consumers about the safety and efficacy of nicotine-replacement therapies to show the products’ value, according to recent research.
Many employers still hold a short-sighted view of the cost of smoking cessation therapies, panelists at an American University webinar said Nov. 16.
Participants at an FDA workshop will consider issues that could influence whether the agency extends the use of nicotine-replacement therapies beyond the current 12-week indication